DE-101 ophthalmic suspension
DrugOphthalmic suspention; QID
NCT Number: NCT01118754
The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Inglewood, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ophthalmic suspention; QID
ophthalmic suspension vehicle; QID
Time frame: 8 weeks
Time frame: 8 weeks
Santen Inc.
Industry
Phase I/II Prospective, Randomized, Double Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Compared to Placebo for the Treatment of Dry Eye Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07089511
Dry Eye, Dry Eye Syndromes
Milan, Italy
View Trial DetailsNCT06346340
Dry Eye, Dry Eye Syndromes
Laguna Hills, California, United States
View Trial DetailsNCT07675460
Acne Cystic, Choroidal Thickness
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT04418999
Allergy, Corneal Diseases
Chicago, Illinois, United States
View Trial Details